By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aurinia (Formerly Known as Isotechnika Pharma Inc.) 

5120 - 75th Street

Edmonton  Alberta  T6E 6W2  Canada
Phone: 780-487-1600 Fax: 780-484-4105


Key Statistics

Ownership: Public

Web Site: Aurinia
Symbol: AUPH

Company News
Aurinia (AUPH) Announces Results From Japanese Phase I Ethnic Bridging Study For Voclosporin 2/14/2017 6:13:38 AM
Aurinia (AUPH) CEO Resigns, Founder Returns to Helm Company 2/7/2017 6:30:56 AM
Aurinia (AUPH) Selects Worldwide Clinical Trials As Its CRO For Phase 3 Lupus Nephritis Trial 1/27/2017 8:27:12 AM
JPM17: Aurinia (AUPH)’s CEO on a Mission to Improve the Way Lupus Nephritis is Treated 1/10/2017 7:09:45 AM
Aurinia (ISA.TO) Closes US$28 Million Financing 12/29/2016 8:24:57 AM
Aurinia (ISA.TO) Announces US$25.0 Million Bought Deal Financing 12/22/2016 11:22:58 AM
Aurinia (ISA.TO) Announces Long-Term Manufacturing Collaboration Agreement With Lonza Inc. For Clinical And Commercial Supply Of Voclosporin 12/20/2016 1:06:03 PM
Aurinia (ISA.TO) Announces Appointment Of Biotech Industry Leader Jeffry Randall To Its Board Of Directors And Audit Committee 12/13/2016 9:31:56 AM
Aurinia (ISA.TO) Confirms Receipt Of FDA End of Phase II Meeting Minutes 12/13/2016 8:41:26 AM
Aurinia (ISA.TO) Highlights Renal Function Data From Global Phase IIb AURA Study Of Voclosporin For Lupus Nephritis At American Society of Nephrology Kidney Week 2016 11/21/2016 11:01:53 AM